62 reports

  • Scope and Methodology

XOLAIR (OMALIZUMAB) Chapter ##: Pipeline Disruptors: Asthma TABLE ##-##: LEADING ASTHMA PRODUCT SALES (GLOBAL), 2016 ($ IN MILLIONS) FIGURE ##-##: ASTHMA MARKET SHOWS CORTICOSTEROIDS TREATMENT OF CHOICE, SALES BY DRUG TYPE 2010-2016 ($ MILLIONS) Chapter ##: Pipeline Dis

  • Breast Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Gilead Sciences Disrupts HCV Market Figure ##-##: Gilead Sciences Dominates HCV Market, Displaces Current Therapies ($ millions) Bristol-Myers Squibb - Opdivo Disrupts Monoclonal Antibody Performance in Cancer Figure ##-##: Monoclonal Antibodies in Cancer Treatment, Opdivo

  • Breast Cancer
  • Leukemia
  • Oncology
  • World
  • Market Size

Drivers and their Impact Driver Hospitals Pharmaceutical Stores Increase in Prevalence of Breast Cancer Low Low Unmet Medical Needs ## ## ## ## ## High High Low Low ## ## ## ## ## High High Increase in Prevalence of Breast Cancer Americas Low Low ## ## ## ## ## High High Low Low

  • Breast Cancer
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.
  • PIPELINE BY ASTRAZENECA PLC, H2 2018

It is also developing new approaches to the treatment of asthma.

  • Breast Cancer
  • Therapy
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Breast Cancer
  • General Medicine And Specialty Medicine
  • United States
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Breast Cancer
  • Therapy
  • United States
  • World
  • Product Initiative

One such trend is the increase in awareness.

  • Breast Cancer
  • United States
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

It was under development for the treatment of psoriasis and COPD (Chronic Obstructive Pulmonary Disease) and severe asthma.

  • Breast Cancer
  • Cytokine
  • United States
  • Product Initiative
  • Dompe Farmaceutici S.p.A.

It was under development for the treatment of psoriasis and COPD (Chronic Obstructive Pulmonary Disease) and severe asthma.

  • Breast Cancer
  • Cytokine
  • Therapy
  • Transplantation
  • Dompe Farmaceutici S.p.A.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Breast Cancer
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Breast Cancer
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Products

The molecules developed by companies in Phase III, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Breast Cancer
  • China
  • Turkey
  • Product Initiative
  • Shenogen Pharma Group

The company' s pharmaceutical products comprises of inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Breast Cancer
  • Oncology
  • World
  • Product Initiative
  • Pfizer Inc.

Secondary endpoints include asthma exacerbation rate and the degree of asthma symptom control.

  • Biotech
  • Breast Cancer
  • Therapy
  • United States
  • Product Initiative

Secondary endpoints include asthma exacerbation rate and the degree of asthma symptom control.

  • Breast Cancer
  • Cancer
  • United States
  • World
  • Product Initiative

Similarly, the Universities' portfolio in Preclinical, Discovery and Unknown stages comprises ##, ## and ## molecules, respectively.

  • Breast Cancer
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Amgen Inc.
  • PIPELINE BY ASTRAZENECA PLC, H2 2018

It is also developing new approaches to the treatment of asthma.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative

The companys pharmaceutical products comprises of inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Breast Cancer
  • United States
  • World
  • Product Initiative
  • Pfizer Inc.

## Infection ## Vitamin B## Deficiency ## Human Immunodeficiency Virus Type ## Infection ## Cytomegalovirus Infection ## Hepatitis A Infection ## Hepatitis C Infection ## Kidney Disease ## Metastatic Melanoma ## Lung Cancer ## Mycobacterium avium ## Tuberculosis ## Preeclampsia ## Thyroid Cancer ## Toxopl

  • Anesthetics
  • Breast Cancer
  • Targeted Therapy
  • Transplantation
  • Roche Group

The companys pharmaceutical products comprises of inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Breast Cancer
  • Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Breast Cancer
  • United States
  • World
  • Company Sales
  • Product Initiative

It is also developing new approaches to the treatment of asthma.

  • Breast Cancer
  • Pharmaceutical
  • Japan
  • United States
  • Daiichi Sankyo Company
  • Daiichi Sankyo Company, Limited - Preclinical, 2016

CS-## was under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  • Breast Cancer
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company

PRESENTED POST APPROVAL STUDY RESULTS AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE THAT DEMONSTRATED THE ALAIR™ BRONCHIAL THERMOPLASTY SYSTEM REDUCED COMPLICATIONS, INCLUDING SEVERE ASTHMA EXACERBATIONS AND ASTHMA-RELATED HOSPITALIZATIONS, IN ADULT PATIENTS WITH SEVERE

  • Breast Cancer
  • Medical Device
  • Australia
  • United States
  • Verisante Technology, Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I, IND/ CTA Filed and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Breast Cancer
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Amgen Inc.

It was also under development for the treatment of rheumatoid arthritis (RA), mantle cell lymphoma, T-cell acute lymphoblastic leukemia (T-ALL), marginal zone lymphoma and diffuse large Bcell lymphoma and allergic asthma.

  • Breast Cancer
  • Pharmaceutical
  • United States
  • Company
  • Infinity Pharmaceuticals, Inc.

It is also developing new approaches to the treatment of asthma.

  • Breast Cancer
  • Therapy
  • United States
  • Company
  • G1 Therapeutics, Inc.
  • Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

It is developing products for the treatment of atopic dermatitis; extensively drug-resistant tuberculosis (XDR) and multi drug resistant (MDR) and totally drug resistant (TDR) tuberculosis (TB); asthma and cancer, among others.

  • Breast Cancer
  • Therapy
  • United States
  • Product Initiative
  • Syros Pharmaceuticals, Inc.

NO has a solid place in asthma management.

  • Breast Cancer
  • Drug Test
  • United States
  • Alere Inc.
  • Dräger Group
  • PIPELINE BY ABBVIE INC, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Breast Cancer
  • Oncology
  • Ovarian Cancer
  • Therapy
  • AstraZeneca PLC